Dr. Mark S. Friedman, MD

Dr. Friedman practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Friedman's NPI, 1538346705, was assigned on January 30, 2008. Dr. Friedman graduated from SUNY Downstate Health Sciences University in 2005. Dr. Friedman holds Florida license ME109919.

Dr. Friedman's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Friedman's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. Dr. Friedman is also affiliated with Providence Regional Medical Center Everett. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Friedman to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Friedman practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Friedman's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Friedman is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Dr. Friedman's licenses on file in 3 states: Florida, District of Columbia and Virginia.

Dmand AI lists chronic inflammatory bowel disease (IBD), colonoscopy, fatty liver, hepatitis c and upper GI endoscopy among the conditions Dr. Friedman treats.

CMS data shows 238 Medicare services from Dr. Friedman across 8 procedure codes in 2024, for 219 Medicare patients. Medicare paid $28,688 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 219 Medicare patients who saw Dr. Friedman in 2024. The largest group is 65 to 74, with 119 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.13, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Friedman's median patient age at 67, with 55% women.

In 2024, Dr. Friedman wrote 240 Medicare Part D claims for 198 patients. 88% of them were for generic drugs. CMS names the drug for 193 of them, across 5 drugs with 11 or more claims each, at $5,061 in total drug cost. In 2023, CMS named 217 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Friedman for performance year 2024, reported as part of a group. Dr. Friedman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Friedman as offering telehealth. CMS counts 152 procedures of colonoscopy by Dr. Friedman, more than 89% of the clinicians it reports for that procedure.

Dmand AI links 82 papers to Dr. Friedman, published from 2005 to 2025. 2015 was the busiest year, with 3. The most frequent topics are Echocardiography, Health Care Costs and Heart Failure. Dr. Friedman has published most often in Am J Cardiol. Dr. Friedman's most frequent co-authors are Mark Friedman, MD, Mark Joel Friedman, MD and Zain I. Khalpey, MD.

CMS Open Payments shows 26 general payments to Dr. Friedman from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 73% of the total. Madrigal Pharmaceuticals paid the most, $4,778.

Dmand AI lists 1 award for Dr. Friedman, most recently CMS Stage 1 2012 in 2012.

Dr. Friedman graduated from SUNY Downstate Health Sciences University in 2005. Dr. Friedman is a member of ACG.

Dr. Friedman is in network with 10 carriers, including Excellus BlueCross BlueShield, Cigna and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.